Value Investing Research & Market Analysis

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

9.540 +0.510 (+5.65%)
Delayed Quote Updated: 12:07 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Telix Pharmaceuticals Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Telix Reports Third Quarter 2026 Financial Performance
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and Ekalia to Collaborate on Astatine-211 Production in the U.S.
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
From Profound Medical Corp.
Via GlobeNewswire
News headline image
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
From Telix Pharmaceuticals Limited; ITM Isotope Technologies Munich SE
Via GlobeNewswire
News headline image
FDA Approves Telix’s Brain Cancer Imaging Drug Pixclara
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Appoints David Gill as Chair
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Host R&D Day in New York City on September 22, 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix H1 2026 Results: Investor Webcast Notification
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
FDA Alignment to Advance ProstACT Global Phase 3 Trial
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and United Imaging Announce Strategic Theranostics Collaboration
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
TLX101-Px (Pixlumi®) MAA Accepted in Europe
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and Regeneron Announce Strategic Radiopharma Collaboration
From Telix Pharmaceuticals Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.